{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:53:54Z","timestamp":1761490434670,"version":"3.37.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1092856"],"award-info":[{"award-number":["1092856"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1093\/annonc\/mdx796","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T21:31:47Z","timestamp":1513373507000},"page":"737-743","source":"Crossref","is-referenced-by-count":25,"title":["Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters\u2014patient-centered end points in trials of maintenance therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"M.","family":"Friedlander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lesoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Malander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Petru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdx796_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"Cancer J Clin"},{"issue":"30","key":"10.1093\/annonc\/mdx796_bb0015","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdx796_bb0020","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdx796_bb0025","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO\u2014The MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdx796_bb0030","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90\u2013labeled hmfg1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdx796_bb0035","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1093\/annonc\/mdx796_bb0040","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2009.21.9691","article-title":"Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel\/platinum-based chemotherapy: final results of the after-6 protocol 1","volume":"27","author":"Pecorelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdx796_bb0045","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdx796_bb0050","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1093\/annonc\/mdx796_bb0055","first-page":"CD007414","article-title":"Maintenance chemotherapy for ovarian cancer","volume":"29","author":"Mei","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdx796_bb0060","doi-asserted-by":"crossref","first-page":"12.","DOI":"10.1016\/S0959-8049(11)70122-8","article-title":"Quality of life outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"47","author":"Monk","year":"2011","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdx796_bb0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdx796_bb0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1093\/annonc\/mdx796_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"1","key":"10.1093\/annonc\/mdx796_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx796_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"year":"2001","series-title":"EORTC QLQ-C30 Scoring Manual, 3rd edition","author":"Fayers","key":"10.1093\/annonc\/mdx796_bb0090"},{"issue":"11","key":"10.1093\/annonc\/mdx796_bb0095","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/(SICI)1097-0258(19980615)17:11<1215::AID-SIM844>3.0.CO;2-Y","article-title":"Quality adjusted survival analysis with repeated quality of life measures","volume":"17","author":"Glasziou","year":"1998","journal-title":"Stat Med"},{"issue":"2","key":"10.1093\/annonc\/mdx796_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2015.11.030","article-title":"Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance","volume":"140","author":"Minion","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx796_bb0105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/2193-1801-2-391","article-title":"Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone","volume":"2","author":"Lee","year":"2013","journal-title":"SpringerPlus"},{"issue":"5","key":"10.1093\/annonc\/mdx796_bb0110","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1525-1438.2005.00141.x","article-title":"Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy","volume":"15","author":"Le","year":"2005","journal-title":"Int J Gynecol Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/3\/737\/24530914\/mdx796.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:53:46Z","timestamp":1624697626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419355073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0923753419355073"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx796","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}